Stemline Therapeutics, Inc.

This study is for people with a certain type of advanced breast cancer (ER+/HER2-). It tests the drug elacestrant together with other targeted therapies to see if these combinations are safe and can help control the cancer. About 435 adults will take part. The goal is to find the…

This study tests a new drug combination for adults with a specific type of acute myeloid leukemia (CD123+ AML) who cannot receive intensive chemotherapy. The treatment adds tagraxofusp to two standard drugs (venetoclax and azacitidine) to see if it improves remission rates. About…

This early-stage study tests a new drug called MEN2501 in about 100 adults with ovarian cancer that has stopped responding to platinum-based chemotherapy. The main goals are to find a safe dose and check for side effects. Researchers will also watch for signs that the drug is shr…

This study tests a new drug, elacestrant, against standard hormone therapy in 4,220 people with a common type of early breast cancer that has spread to lymph nodes and has a high chance of returning. The goal is to see if elacestrant can better prevent the cancer from coming back…

This study tests a new drug called MEN2312 for people with advanced breast cancer that cannot be cured. The drug works by blocking a protein (KAT6) that helps cancer grow. The study will find the safest dose and see if it shrinks tumors or slows the disease. About 240 adults will…

This study tests a combination of two drugs, elacestrant and abemaciclib, in people with a specific type of breast cancer (ER-positive, HER2-negative) that has spread to the brain. The goal is to see if the combination can shrink or control brain tumors. About 73 adults are being…